BIRC3 induces the phosphoinositide 3-kinase-Akt pathway activation to promote trastuzumab resistance in human epidermal growth factor receptor 2-positive gastric cancer

Figure 5 BIRC3 is correlated with trastuzamab resistance and poor prognosis and the in human epidermal growth factor receptor 2-positive gastric cancer patients. A: Immunohistochemistry (IHC) staining for BIRC3 in gastric cancer (GC) tissues were shown; B: 28 human epidermal growth factor receptor 2 (HER2)-positive patients were stratified into negative and positive groups according to IHC staining for BIRC3; C: The IHC results demonstrated significantly higher expression levels of BIRC3 in the trastuzumab resistant group compared to the sensitive group. Kaplan-Meier analysis of overall survival in HER2-positive GC patients was performed based on BIRC3 levels. IHC: Immunohistochemistry.